- Home
- IDAI vs GLMD Comparison
IDAI vs GLMD Comparison
Compare IDAI & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDAI
- GLMD
- Stock Information
- Founded
- IDAI 2016
- GLMD 2000
- Country
- IDAI United States
- GLMD Israel
- Employees
- IDAI N/A
- GLMD N/A
- Industry
- IDAI Computer Software: Prepackaged Software
- GLMD Biotechnology: Pharmaceutical Preparations
- Sector
- IDAI Technology
- GLMD Health Care
- Exchange
- IDAI Nasdaq
- GLMD Nasdaq
- Market Cap
- IDAI 4.9M
- GLMD 4.1M
- IPO Year
- IDAI N/A
- GLMD 2014
- Fundamental
- Price
- IDAI $3.16
- GLMD $2.06
- Analyst Decision
- IDAI
- GLMD Hold
- Analyst Count
- IDAI 0
- GLMD 1
- Target Price
- IDAI N/A
- GLMD N/A
- AVG Volume (30 Days)
- IDAI 67.5K
- GLMD 417.4K
- Earning Date
- IDAI 08-12-2025
- GLMD 08-27-2025
- Dividend Yield
- IDAI N/A
- GLMD N/A
- EPS Growth
- IDAI N/A
- GLMD N/A
- EPS
- IDAI N/A
- GLMD N/A
- Revenue
- IDAI $3,054,143.00
- GLMD N/A
- Revenue This Year
- IDAI $65.46
- GLMD N/A
- Revenue Next Year
- IDAI $12.00
- GLMD N/A
- P/E Ratio
- IDAI N/A
- GLMD N/A
- Revenue Growth
- IDAI N/A
- GLMD N/A
- 52 Week Low
- IDAI $1.43
- GLMD $1.15
- 52 Week High
- IDAI $18.75
- GLMD $23.80
- Technical
- Relative Strength Index (RSI)
- IDAI 58.37
- GLMD 61.89
- Support Level
- IDAI $2.80
- GLMD $1.87
- Resistance Level
- IDAI $3.53
- GLMD $2.13
- Average True Range (ATR)
- IDAI 0.36
- GLMD 0.13
- MACD
- IDAI 0.04
- GLMD 0.01
- Stochastic Oscillator
- IDAI 58.33
- GLMD 66.79
About IDAI T Stamp Inc.
T Stamp Inc develops and markets identity authentication software solutions for enterprise partners and peer-to-peer markets. The company is engaged in developing proprietary artificial intelligence-powered solutions; researching and leveraging biometric science, cryptography, and data mining to deliver insightful identity & trust predictions while identifying and defending against fraudulent identity attacks, protecting sensitive user information, and extending the reach of digital services through accessibility. The artificial intelligence-powered solutions segment generates revenue principally from software licenses, professional services, and recurring Software-as-a-Service ("SaaS") revenue.
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.